^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    18h
    Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Fred Hutchinson Cancer Center
    New P2 trial
    |
    Jakafi (ruxolitinib) • sirolimus • fludarabine IV • cyclosporin A microemulsion
    6d
    RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Cabaletta Bio | N=18 --> 24
    Enrollment change
    |
    cyclophosphamide • fludarabine IV
    7d
    NKX101-101: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Nkarta, Inc. | Trial primary completion date: Jul 2024 --> Oct 2024
    Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    cytarabine • cyclophosphamide • decitabine • fludarabine IV • NKX101
    8d
    A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) (clinicaltrials.gov)
    P3, N=300, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    cyclophosphamide • bendamustine • Truxima (rituximab-abbs) • fludarabine IV • nemtabrutinib (MK-1026)
    8d
    ZUMA-7: Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P3, N=359, Completed, Kite, A Gilead Company | Active, not recruiting --> Completed
    Trial completion
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    carboplatin • cytarabine • cyclophosphamide • oxaliplatin • Yescarta (axicabtagene ciloleucel) • fludarabine IV • methylprednisolone sodium succinate
    10d
    STAT1 Promotes PD-L1 Activation and Tumor Growth in Lymphangioleiomyomatosis. (PubMed, bioRxiv)
    Although it is known that hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) due to TSC2 gene mutations contributes to aberrant cell growth in LAM lung, tumor origin and invasive mechanism remain unclear...Fludarabine, a potent STAT1 inhibitor, induced the death of TSC2- deficient cells, increased caspase-3 cleavage, and phosphorylation of necroptosis marker RIP1...Interestingly, IFN-γ treatment increased STAT1 phosphorylation and PD-L1 expression, indicating that STAT1 aids TSC2-deficient tumor cells in evading immune surveillance in LAM. Our findings indicate that STAT1 signaling is critical for LAM cell survival and could be targeted to treat LAM and other mTORC1 hyperactive tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • TSC2 (TSC complex subunit 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TSC1 (TSC complex subunit 1) • CASP3 (Caspase 3) • PBX1 (PBX Homeobox 1) • PCNA (Proliferating cell nuclear antigen) • STAT1 (Signal Transducer And Activator Of Transcription 1) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1)
    |
    PD-L1 expression • TSC2 mutation • MTOR mutation
    |
    sirolimus • fludarabine IV
    13d
    Case report: HSV lymphadenitis in immunocompromised patient with CLL. (PubMed, Front Oncol)
    He was diagnosed with Rai Stage I CLL with del6q, without TP53 mutation, and treated with 6 cycles of fludarabine, cyclophosphamide, and rituximab (FCR) 6 years prior...The patient received three courses of dexamethasone and acyclovir, leading to successful clearance of the infection, evidenced by the resolution of his B symptoms. Subsequently, he was treated for the CLL recurrence with rituximab and venetoclax, demonstrating a favorable response with significant improvement in adenopathy and resolution of lymphocytosis...Timely administration of antiviral therapy is crucial for HSV lymphadenitis to prevent rapid progression and debilitating symptoms. This case demonstrates the importance of considering atypical viral infection presentations in CLL patients and emphasizes the necessity of timely and adequate biopsies to differentiate between CLL transformation, HSV lymphadenopathy, and other causes of lymphadenopathy while avoiding unnecessarily aggressive lymphoma therapy.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cyclophosphamide • dexamethasone • fludarabine IV
    14d
    A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors (clinicaltrials.gov)
    P1/2, N=38, Terminated, Hoffmann-La Roche | Completed --> Terminated; Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed beyond Part 1b.
    Trial termination
    |
    TP53 (Tumor protein P53)
    |
    TP53 wild-type
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • topotecan • idasanutlin (RG7388) • fludarabine IV
    15d
    Prognostic feature based on androgen-responsive genes in bladder cancer and screening for potential targeted drugs. (PubMed, BioData Min)
    ARGs played an important role in the progression, immune infiltration, and prognosis of BLCA. The ARGs model has high accuracy in predicting the prognosis of BLCA patients and provides more effective medication guidelines.
    Journal
    |
    CDK6 (Cyclin-dependent kinase 6) • PTK2B (Protein Tyrosine Kinase 2 Beta)
    |
    carmustine • fludarabine IV • AZD8186
    15d
    A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=50, Enrolling by invitation, Dana-Farber Cancer Institute | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    cyclophosphamide • fludarabine IV • CIML NK
    16d
    SELCLAX: Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=42, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2025 --> Jun 2027
    Trial completion date • Combination therapy
    |
    Venclexta (venetoclax) • cytarabine • Xpovio (selinexor) • methotrexate • fludarabine IV • Neupogen (filgrastim)
    18d
    CAR T-cell Therapy in Patients With Renal Dysfunction (clinicaltrials.gov)
    P2, N=20, Recruiting, Northside Hospital, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV
    18d
    Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (clinicaltrials.gov)
    P=N/A, N=13, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2025 --> Sep 2025
    Trial completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600 • BRAF wild-type
    |
    Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    19d
    Analysis of nitrogen metabolism-related gene expression in hepatocellular carcinoma to establish relevant indicators for prediction of prognosis and guidance of immunotherapy. (PubMed, Comput Methods Biomech Biomed Engin)
    This work created a 12-gene signature based on NM, preliminary investigated immune infiltration in two risk categories, and discovered some possible anti-tumor medications. To sum up, our study findings offer fresh perspectives on the roles played by NM-associated genes in HCC development, prognosis, immunological response, and medication screening.
    Journal • IO biomarker
    |
    SPHK1 (Sphingosine Kinase 1)
    |
    Cotellic (cobimetinib) • Mektovi (binimetinib) • cladribine • SCH772984 • REC-4881 • fludarabine IV • pimasertib (AS703026) • hydroxyurea • temuterkib (LY3214996)
    21d
    BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) (clinicaltrials.gov)
    P2, N=27, Recruiting, University of Illinois at Chicago | Trial completion date: Nov 2024 --> Dec 2026 | Trial primary completion date: Nov 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Post-transplantation
    |
    RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    RUNX1 mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation
    |
    cyclophosphamide • fludarabine IV
    22d
    Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia (clinicaltrials.gov)
    P1, N=19, Terminated, M.D. Anderson Cancer Center | Active, not recruiting --> Terminated; Administratively Complete
    Trial termination
    |
    cytarabine • fludarabine IV • Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase) • Starasid (cytarabine ocfosfate)
    22d
    CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=1, Terminated, Celularity Incorporated | N=52 --> 1 | Trial completion date: Feb 2025 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Feb 2024; for business reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cyclophosphamide • CYNK-101 • fludarabine IV • mesna • Proleukin (aldesleukin)
    22d
    Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) (clinicaltrials.gov)
    P1, N=42, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Minimal residual disease
    |
    Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)
    23d
    Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC (clinicaltrials.gov)
    P1/2, N=20, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Feb 2026 --> Jan 2025
    Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
    23d
    Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies (clinicaltrials.gov)
    P1, N=54, Recruiting, Roswell Park Cancer Institute | N=36 --> 54
    Enrollment change • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV
    25d
    MCC-21622: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Jan 2026 --> Mar 2025
    Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    cyclophosphamide • fludarabine IV • PRGN-3007
    28d
    AIM2 promotes the progression of HNSCC via STAT1 mediated transcription and IL-17/MAPK signaling. (PubMed, Cell Signal)
    The STAT1 inhibitor, fludarabine, reduces AIM2 expression and subsequently diminishes cell proliferation. Mechanistically, AIM2 exerts its tumor-promoting effects through the IL-17-MAPK signaling pathway. Collectively, our data demonstrate that AIM2, transcriptionally activated by STAT1, exhibits oncogenic functions by promoting the IL-17-MAPK signaling pathway, suggesting that AIM2 may be a new intervention targets for the diagnostic and treatment of HNSCC.
    Journal
    |
    AIM2 (Absent In Melanoma 2) • IL17A (Interleukin 17A) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    fludarabine IV
    28d
    Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide (clinicaltrials.gov)
    P2, N=27, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2027
    Trial completion date • Trial primary completion date • Post-transplantation
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV
    28d
    MCC-21622: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=88 --> 3
    Enrollment closed • Enrollment change • CAR T-Cell Therapy • Metastases
    |
    cyclophosphamide • fludarabine IV • PRGN-3007
    28d
    CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Wuhan Union Hospital, China
    New P1/2 trial • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide • fludarabine IV
    29d
    ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) (clinicaltrials.gov)
    P1, N=30, Recruiting, Acepodia Biotech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    IL2 (Interleukin 2)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • ACE2016
    29d
    ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors (clinicaltrials.gov)
    P1, N=12, Completed, Acepodia Biotech, Inc. | Recruiting --> Completed | N=36 --> 12
    Trial completion • Enrollment change • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    cyclophosphamide • fludarabine IV • ACE1702
    30d
    HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Baylor College of Medicine | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial primary completion date
    |
    Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
    1m
    Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. (PubMed, Lancet Oncol)
    In patients with heavily pretreated T-cell lymphoma, CTX130 showed manageable safety and a promising objective response rate. This study shows that allogeneic, readily available CAR T cells can be safely given to patients with relapsed or refractory T-cell lymphoma. A next-generation CAR T-cell therapy containing additional potency gene edits (CTX131) is in clinical development.
    P1 data • Journal • CAR T-Cell Therapy
    |
    CD70 (CD70 Molecule)
    |
    cyclophosphamide • fludarabine IV • CTX130 • CTX131
    1m
    TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Chinese PLA General Hospital | Trial completion date: Jul 2027 --> Feb 2028 | Initiation date: Jul 2024 --> Feb 2025 | Trial primary completion date: Jul 2026 --> Feb 2027
    Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV
    1m
    US Zamto-cel Autoimmune Diseases (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Miltenyi Biomedicine GmbH
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • zamtocabtagene autoleucel (MB-CART2019.1)
    1m
    Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2025 --> Jan 2024
    Enrollment closed • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    1m
    A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=141, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Mar 2025 --> Nov 2024
    Enrollment open • Trial initiation date • Metastases
    |
    cyclophosphamide • fludarabine IV • KSQ-004EX
    1m
    CD34+ Transplants for Leukemia and Lymphoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Guenther Koehne | Trial completion date: Oct 2031 --> Mar 2032 | Trial primary completion date: Oct 2031 --> Mar 2032
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    1m
    Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Campath (alemtuzumab) • fludarabine IV • captisol-enabled melphalan
    1m
    Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    cyclophosphamide • fludarabine IV • SENTI-301A
    1m
    TIL Therapy for Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=5, Completed, Inge Marie Svane | Unknown status --> Completed
    Trial completion • Metastases
    |
    IL2 (Interleukin 2)
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    1m
    Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, GC Cell Corporation
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    1m
    225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Feb 2027 --> May 2028 | Initiation date: Oct 2024 --> Jan 2025 | Trial primary completion date: Feb 2027 --> May 2028
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    Darzalex (daratumumab) • sirolimus • melphalan • fludarabine IV
    1m
    Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, The First Affiliated Hospital of Soochow University
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    1m
    BRAVO: Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, University of Florida | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    temozolomide • cyclophosphamide • fludarabine IV
    1m
    NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=35, Recruiting, Fred Hutchinson Cancer Center | N=20 --> 35 | Trial completion date: Oct 2026 --> Mar 2027 | Trial primary completion date: Dec 2024 --> Mar 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)